NCT07325136

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer

Conditions

• Relapsed/Refractory Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	BMS-986525	Specified dose on specified days
DRUG	Nivolumab	Specified dose on specified days

Timeline

• Start date: 2026-02-03
• Primary completion: 2029-04-23
• Completion: 2029-04-24
• First posted: 2026-01-08
• Last updated: 2026-03-09

Locations

11 sites across 5 countries: United States, Italy, Japan, Romania, Spain

Regulatory

• FDA-regulated drug study